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In Ghana, surveillance efforts on antibiotic resistance so far have not covered 
carbapenem resistance. In this study, our aim was to apply phenotypic and genotypic 
methods to identify and characterise carbapenem-resistant (CR) Gram-negative bacteria 
from the hospital environment in Ghana. A collection of 3840 isolates of Gram-negative 
bacilli infections from various clinical specimens was screened for carbapenem 
resistance by disc diffusion for imipenem, meropenem and doripenem. Minimum 
Inhibitory Concentration (MIC) of the CR isolates was determined by E-test for the 
three carbapenems. All the CR isolates were further screened for carbapenemase 
activity by modified Hodge and Boronic-acid disc synergy tests. The CR isolates were 
investigated for the presence of carbapenemase and extended spectrum beta-lactamase 
genes by PCR and confirmed by sequencing. The overall prevalence of carbapenem-
resistant isolates was 2.9% (111/ 3840). Based on the disc diffusion test, prevalence of 
resistance to carbapenems were doripenem (75%), imipenem (66.7%) and meropenem 
(58%). The highest measurable MIC levels (≥32 μg/ml) were observed in 56.8% of CR 
isolates with the non-fermenters Pseudomonas aeruginosa (24.3%) and Acinetobacter 
species (18.9%) disproportionately represented. Phenotypic identification of 
carbapenamase activity occurred in 18.9% of the CR isolates by the modified Hodge 
test and 2.7% by Boronic acid-disc synergy test; 21.6% exhibited carbapenemase 
production by both methods. All the CR isolates carried ESBL genes (blaTEM and 
blaSHV) while 23.4% were carriers of carbapenemase genes of which 14.4% were 
blaNDM-1, 7.2% blaVIM-1 and 1.8% blaOXA-48. Phylogenetically, the CR isolates 






















Gram-negative bacilli are common colonizers of the human intestinal tract and are 
implicated in a wide range of diseases such as pneumonia, meningitis, septicaemia and 
urinary tract infections.
1-5
 They include enterobacteriacae as well as non-fermenters 
such as Pseudomonas aeruginosa and Acinetobacter baumannii. The latter tend to be 
more associated with opportunistic infections in seriously ill, hospitalized and 
immunocompromised patients. Carbapenems are considered a last-resort treatment of 
Gram-negative infections, and emergence and spread of carbapenem resistance 
constitute a very important public health problem.
1
 The mechanisms of carbapenem 
resistance in Gram-negative bacilli involves (i) hyper production of ESBL combined 
with reduced outer membrane permeability and/or (ii) carbapenemase production.
1,6
 
Following the discovery of NmcA in Enterobacter cloacae as the first carbapenemase 
in 1993,
7
 carbapenemases have gained worldwide recognition due to their association 
with outbreaks and the ease with which they can spread.
1,8
 The enzymes have been 
characterised as various classes of carbapenemases including the most common types: 
the New Delhi metallo-β-lactamases (NDM), Verona integron-encoded metallo-β-
lactamases (VIM), oxacillinase-48 (OXA-48), imipenem-resistant Pseudomonas-1 
(IMP-1) β-lactamase and Klebsiella pneumoniae carbapenemases (KPCs). The genes 





Although carbapenemase-producing organisms are a global problem, the majority of the 
epidemiological data on the subject relate to the developed world. Recently, a few 
African countries have extensively investigated carbapenemase producers among Gram-













 More importantly, in 
terms of resistance to carbapenems, in sub-Saharan Africa there are limited data 
available to ascertain the extent of the spread of carbapenemase gene carriers. Current 
studies show there is a lack of interest, poor implementation of surveillance studies and 
an unsystematic approach to carrying out research studies on carbapemase-producing 
bacteria in this part of the sub-region.
8
 Recently, a nationwide laboratory based 
antimicrobial resistance study carried out in Ghanaian health care facilities by Opintan 
et al.
9
 reported no data on the prevalence and distribution of CRE, despite the fact that 
there are increased numbers of multidrug-resistant organisms in the country.
 
To fill this 
research gap, we applied various techniques to identify and characterise carbapenem-
resistant (CR) Gram-negative organisms and their resistance genes from the hospital 
environment in Ghana.  
 
2.0 METHODS 
2.1 Study Sites and Bacteria Isolates  
A prospective study was carried out in four selected hospital laboratories in Ghana from 
September 2012 to September 2014. The study hospitals included Korle-Bu Teaching 
Hospital in the Greater Accra Region (KBTH), Effia-Nkwanta Hospital (ENH) in the 
Western Region, AngloGold Mines Hospital (AMH) in the Ashanti Region and Ho 
Regional Hospital (HRH) in the Volta Region. These hospitals were selected to 
represent the different types of hospitals in Ghana including tertiary hospitals (KBTH), 
regional hospitals (HRH and ENH) and district hospitals (AMH).  
 
A total of 3840 Gram-negative bacilli isolates from various clinical specimens in the 
study hospitals were collected, and Figure 1 provides a schematic representation of the 
investigations carried out on the isolates. Multidrug resistant CR isolates were identified 
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using the disc diffusion technique of the British Society for Antimicrobial 
Chemotherapy (BSAC) method. Multidrug resistance (MDR) was defined as resistance 
to three or more classes of antimicrobial agents.
10,11
 The CR study isolates were 
identified to the species levels by the use of Vitek 2 automated Compact system 
(BioMérieux, France). Quality control strains including Escherichia coli ATCC 25922, 
a known susceptible strain to carbapenems, and Klebsiella pneumoniae carbapenemase 
positive NCTC 13438 were included as controls in the identification process.  
 
2.2 Antimicrobial Susceptibility Testing 
All the MDR isolates were re-tested using three carbapenem discs (Oxoid Ltd, 
Basingstoke, UK); imipenem, meropenem and doripenem according to the BSAC disc 
diffusion method
10
 on Mueller-Hinton agar (MHA), (Biotec Ltd, UK). A reference 
strain of Escherichia coli ATCC 25922 was included as a negative control organism. 
Zone sizes were interpreted based on the BSAC breakpoints.
11 
For isolates with 
diameters ≤15 mm, minimum inhibitory concentrations (MICs) were determined using 
the E-test method
11
, and resistance was defined as isolates with MIC against the same 
carbapenems of ≥4 µg/ml according to BSAC breakpoints. Additionally, E-test strips 
(BioMérieux, France) for imipenem, meropenem and ertapenem showing MIC values 
greater or within 2 to 4, 2 to 4, and 1μg/ml levels, respectively, were considered 
carbapenemase producers.
12
 The non-fermenting bacilli were excluded for ertapenem 
disc and E-test strip determination due to lack of activity against these organisms.  
2.3 Phenotypic based methods for detection of carbapenem-resistant organisms 
All the CR isolates were screened for carbapenemase activity by modified Hodge and 
Boronic-acid disc synergy tests
13,14
 and beta-lactamase activity by nitrocefin assay.
15
 





 Briefly, the indicator organism Escherichia coli ATCC 25922 was 
prepared by obtaining an overnight broth culture which was adjusted to 0.5 McFarland 
turbidity standard followed by a 10-fold dilution in saline. This broth was then used to 
inoculate the surface of plates of Mueller-Hinton agar (Biotec Ltd, UK) by swabbing 
and meropenem (10μg) was placed at the centre. Three to five colonies of the test 
organisms were used to inoculate the plate in a line straight from the edge of disc to the 
end of the plate and incubated overnight at 35-37ºC for 16-24 hours. The plate was read 
and interpreted as positive test when a clover-leaf like indentation of the Escherichia 
coli ATCC 25922 grew along the test organism growth streak within the disc diffusion 
zone. 
The Boronic-acid disc synergy test was performed as described by Doi et al.
17 
Carbapenem discs containing 10μg each of imipenem, meropenem and ertapenem were 
supplemented with 20 μl of 20 mg/ml 3-aminophenyl-boronic acid (APB) and dissolved 
in dimethyl sulphoxide (DMSO; Sigma-Aldrich Company Ltd Dorset, UK) to yield a 
400 μg/ml final concentration. A suspension of the test organism was prepared 
according the same protocol described above and then used to swab the surface of a 
MHA plate. The supplemented discs of imipenem, meropenem and ertapenem 
containing 400 μg/ml each and un-supplemented discs of each antimicrobial 
respectively were placed far apart on the plate and incubated at 35-37ºC in air for 16-18 
hours. A positive test for KPC enzyme production was recorded when the measured 
diameter of the growth-inhibitory zone around each carbapenem disc with boronic acid 
was ≥5 mm more than that around the disc containing the carbapenem alone. 
In the evaluation of beta-lactamase activity of the CR isolates by nitrocefin assay, 
preparation of β-lactamase extracts from the isolates was first done using the technique 
described by Dai et al.
15
 Subsequently, the β-lactamase concentration of the extracts 
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was determined by a microplate assay as follows. In each well, 10 µl of collected extract 
was added to a 96-well plate. Total volume was adjusted to 50 µl per well with βL 
Assay Buffer (100 mM Sodium phosphate, pH 7.0). Reaction mixture was prepared 
according to the manufacturer's instructions. In each well, a total reaction mix of 50 µl 
was prepared comprising βL Assay Buffer of 48µl and 2µl of nitrocefin solution. 
Reaction mix was added to the extract in each well, and was then thoroughly mixed, and 
the absorbance of the solution was measured at 390 and 486 nm every minute for a 15-
minute period using a plate reader (Tecan Infinite
®
 200 PRO Männedorf, Switzerland). 
Positive controls were prepared in βL Assay Buffer and 10 µl of the diluted positive 
control pipetted into the desired well. Double distilled water was included as a negative 
control. The volume was adjusted to 50 µl with βL Assay Buffer. For the blank, 10 µL 
sodium phosphate buffer was used and adjusted in the same way as the positive control. 
The mixture was then incubated at 30°C for 1 hour.  
2.4 Analysis of Carbapenemase and Extended Spectrum β-lactamase Genes 
DNA extraction of the CR isolates was done using the QiaAmp mini Kit (Qiagen, 
Hilden, Germany). All the 111 CR isolates were investigated for the presence of 
carbapenemase genes by PCR using primers from the five most common genes: New 
Delhi metallo-beta-lactamase-1 (NDM-1), Klebsiella pneumoniae carbapenemase-1 
(KPC-1), Verona integron-encoded metallo-β-lactamase-1 (VIM-1), Oxacillinase-48 
(OXA-48) and Imipenem-resistant Pseudomonas-1 (IMP-1). The primers were 
identified from Poirel et al.
18
 (Supplementary Table 1). Primers identified by 
Schlesinger et al.
19
 were also used to amplify regions of the extended spectrum β-
lactamase genes (blaTEM and blaSHV) in the CR study isolates (Supplementary Table 
1). Different PCR cycling conditions were employed for carbapenemase and extended 
spectrum β-lactamase genes (Supplementary Table 1). Two µl of all the PCR reaction 
mixtures were separated by 2.0% agarose gel electrophoresis, visualized with ethidium 
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bromide staining and UV illumination, and then photographed with a gel documentation 
system (Gel Doc 2000; Bio-Rad, UK). Purified 26 positive carbapenemase products 
including positive control strains were prepared and sent to Eurofins Genomics, 
Ebersberg, Germany for sequencing. 
 
2.5 Data Analysis 
Data from the study were entered into Microsoft Excel and analyzed in Stata (v 7.0; 
Stata Corp, College Station, TX). Descriptive statistics were carried out on the data and 
the results summarized in tables and graphs. The descriptive statistics included 
frequencies and prevalence of various Gram-negative bacteria, their antibiograms, and 
distribution of carbapenemase resistance genes. The sensitivity and specificity of 
Modified Hodge and Boronic Acid-Disc Synergy tests in the detection of 
carbapenemase activity compared with PCR-based detection of carbapenemase genes, 
were evaluated based on the formula described by Pasteran et al.
20
 
2.6 Ethical Considerations 
The study was approved by the Ethical Committee of the School of Biomedical and 
Allied Health Sciences, University of Ghana (Manuscript Ethics Identification Number: 
SAHS-ET/SAHS/PSM/ML/05/AA/26A/2012-2013). As the samples used in the study 
were archived isolates, we could not obtain patients’ consent for use of their clinical 
data. However, all patients’ data and isolates were de-identified to ensure anonymity. 
 
3.0 RESULTS 
3.1 Carbapenem Resistant Isolates Demographics and Characteristics 
A total of 111 CR isolates were identified from screening 3840 Gram-negative bacilli 
isolates. The CR isolates were from 55 male and 56 female patients with ages between 3 
days and 91 years. The 111 CR isolates comprised 51 Pseudomonas aeruginosa, 31 
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Acinetobacter species, 12 Escherichia coli, 7 Pseudomonas putida, 3 each of Klebsiella 
pneumoniae and Enterobacter cloacae, and 1 each of Cronobacter sakazakii, 
Providencia stuartii, Shigella sonnei and Sphingomonas paucimobilis. The organisms 
were isolated from 10 specimen types but most of the isolates were from wound (47) 
and urine (31).  
 
3.2 Antibiogram of Carbapenem Resistant Isolates 
Based on the disc diffusion test, prevalence of resistance to carbapenems were 
doripenem (75%, n=83), imipenem (66.7%, n=74) and meropenem (58%, n=64). The 
highest measurable MIC levels were observed in 56.8% (63) of CR isolates at ≥32 
μg/ml, of which relatively high prevalence of 24.3% (12) and 18.9% (6) were detected 
in Pseudomonas aeruginosa and Acinetobacter isolates, respectively (Figure 2).  
3.3 Carbapenemase activity based on phenotypic tests 
Details of the carbapenemase activity among the CR isolates are shown in Table 2. 
Phenotypic identification of carbapenamase activity was revealed in 21/111 (18.9%) of 
the CR isolates by the modified Hodge test (MHT) and 3/111 (2.7%) by Boronic acid-
disc synergy test (BADST). None of the CR isolates were positive for both MHT and 
BADST phenotypic test. The three Enterobacter cloacae isolates included in the study 
were the only isolates, which showed positivity from the BADST screen.  
3.4 Phenotypic and genotypic correlation of carbapenem-resistant isolates 
The phenotypic and genotypic correlation of CR isolates is shown in Table 1. The 21 
MHT positive isolates included 13 Acinetobacter spp., 6 Pseudomonas spp. and 2 
Klebsiella pneumoniae isolates, none of which were detected by BADST screen as 
positive. The two Klebsiella pneumoniae MHT positive isolates were detected by PCR 
as OXA-48 producers, while one of the MHT positive Acinetobacter spp. was a NDM-1 
producer. The only remaining CR Klebsiella pneumoniae isolate included in the study, 
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showed a negative result for MHT, BADST as well as KPC resistance gene. 
Carbapenemase resistance genes, VIM-1, KPC-1 and IMP-1 were undetected by MHT 
as carbapenemase-producing isolates. A correlation was observed between MHT 
positivity and PCR assay for OXA-48 gene positivity. There was no correlation between 
BADST positivity and PCR-based results. Clearly, phenotype-based tests were less 
efficient in detecting carbapenemase activity considering the percentage sensitivity and 
specificity values when compared with the PCR-based assay results obtained in this 
study (Table 2). 
3.5 Distribution of Carbapenemase-producing Genes and Phylogenetic Analysis 
Based on the PCR assay, 26/111 (23.4%) of the bacterial genomic DNA samples were 
PCR-positive for carbapenemase genes, of which 14.4% (16) were blaNDM-1, 7.2% (8) 
blaVIM-1 and 1.8% (2) for blaOXA-48 genes. As shown in Figure 3, the highest 
carbapenemase gene prevalence was from Acinetobacter species (9 NDM-1 positives) 
and Pseudomonas aeruginosa (2 NDM-1 and 7 VIM-1), followed by Escherichia coli 
(3 NDM-1), Klebsiella pneumoniae (2 OXA-48), one VIM-1 for Pseudomonas putida 
isolate, and one each NDM-1 for Providencia stuartii and Shigella sonnei, respectively. 
No carbapenemase encoding genes were found in the isolates identified as Enterobacter 
cloacae, Cronobacter sakazakii and Sphingomonas paucimobilis.  
 
Of the 26 carbapenemase producers, 23 (88.5%) were isolated in KBTH and these 
included producers of NDM-1 and VIM-1 by several Gram-negative organisms 
(Acinetobacter spp., Pseudomonas aeruginosa, Escherichia coli, Pseudomonas putida, 
Providencia stuartii) but not OXA-48 (Table 3). The other three hospitals each had one 
carbapenemase producer which included one Klebsiella pneumoniae OXA-48 producer 





Phylogenetic analyses were carried out for OXA-48, VIM-1 and NDM-1 of the CR 
isolates in comparison with GenBank established strains using control strains. 
Unfortunately, two of the PCR-positive carbapenemase genes, VIM-1 positive 
Pseudomonas putida and NDM-1 positive Acinetobacter species, including the positive 
NDM-1 control strains failed to yield substantial sequenced data to be added for their 
genetic relationships. The phylogenetic analyses showed an unevenly high level of 
heterogeneity among the CR isolates harbouring carbapenemase encoding genes; cluster 




This study had an overall CR prevalence of 2.9% from total Gram-negative bacterial 
pathogens while 23.4% of the CR isolates were PCR positive for known carbapenemase 
genes. It is worth noting that carbapenem antimicrobials are currently excluded from the 
Ghana Ministry of Health essential drug list following strict adherence to antimicrobial 
usage policy,
 21
 and so carbapenem use in Ghana is very low. However, the 
effectiveness of meropenem and its extended use for children was later recommended 
for patients in hospitals with serious infections around 2011. Presumably, the low-level 
usage of carbapenems may have contributed to this remarkably low prevalence rate of 
resistance in the country’s hospitals. The present overall prevalence of carbapenem 
resistance was relatively low when compared with a similar study in tertiary hospitals in 
Nigeria where, 5.5% (10/182) Gram-negative isolates were carrying recognised 
carbapenemase genes, mainly, metallo-β-lactamase carbapenemases.
6
 While the relative 
prevalence of carbapenem resistance in Ghana is low, it is troubling that there is a 
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measurable carriage rate in a country with exceptionally low levels of carbapenem 
usage. 
 
We observed high levels of resistance among some CR isolates in this study, which 
could have serious public health implications, as carbapenems are considered as a last-
resort for treatment for bacterial infections. For example, in the disc diffusion test, 
resistance to meropenem, imipenem and doripenem was observed in all the CR isolates 
of Klebsiella pneumoniae, Enterobacter cloacae, and Shigella sonnei. Additionally, in 
the MIC E-test assays, 56.8% (63) of CR isolates showed complete resistance to 
imipenem, meropenem and ertapenem at ≥32 µg/ml. The prevalence of ertapenem 
resistance among the carbapenemase producers was 2.7% and all of the ertapenem-
resistant isolates were susceptible to meropenem in the E-test. This concurs with the 
observation of Anderson et al.
16
 that in vitro ertapenem resistant isolates may remain 
susceptible to other carbapenems. 
 
Sensitivity and specificity of phenotype-based tests (MHT and BADST) in this study 
showed no corresponding results with the molecular assay (PCR-based) employed. This 
concurs with studies by Nordmann et al.
1
 and Doyle et al.
22
 who confirmed low 
sensitivity of <12% for MBL detection by the phenotype-based tests, partly due to false-
positivity resulting from ESBLs and AmpC co-existing with porin which mimick 
carbapenemase activity. Previous studies by Hara et al.
12
 and Galani et al.
23 
also 
confirmed MHT was unable to detect weak VIM and NDM carbapenemase genes, 
though the majority of VIM-1 and NDM-1-producing genes were detectable in 





described the boronic acid test as the most specific and sensitive (with meropenem and 
imipenem discs) for detection of KPC in Klebsiella pneumoniae isolates, only when the 
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corresponding organisms existed without the presence of AmpC β-lactamase 
enzyme.
13,24
 The inconsistency could be due to the presence of metallo-β-lactamases in 
strains harbouring AmpC genes (ACC, CIT, DHA, EBC, FOX and MOX), which 
according to Hara et al.
12
 are largely undetectable by MHT and BADST techniques.  
 
In this study, 21.6% of the CR isolates harboured Class B carbapenemases (NDM-1 and 
VIM-1 genes), particularly Pseudomonas aeruginosa and Acinetobacter species. By 
comparison, a study in Iran showed that 33% of CR Pseudomonas aeruginosa 
harboured a blaVIM gene
25
 while another study in India showed that 36% of CR 
Acinetobacter species carried a blaIMP-1 gene.
26
 No IMP-1 and KPC-1 genes were 
detected from Ghanaian CR strains. Detection of IMP-1 genes in Africa have been 
described as rare since their presence have been predominantly observed in China, 
Japan, and Australia.
27
 A study by Lee et al.
28
 suggested that success of blaKPC spread 
depends on certain clones of plasmids that are particularly suited to Klebsiella 
pneumoniae isolates compared with other Gram-negative bacterial pathogens. In the 
current study, there were only three K. pneumoniae isolates, which could have reduced 
the chance of detecting the KPC-1 gene. Interestingly, two of the K. pneumoniae 
isolates haboured the OXA-48 gene. This is the first time this important carbapenemase 
gene has been observed in Ghana. OXA-48 gene was first detected in Turkey in 2004 
and had since spread to Middle East and beyond, 
29
 including known European 






 and recently in Denmark, 
Hungary, Romania and Spain.
33
 A study carried out in Senegal identified the emerging 
danger of OXA-48 genes in the country’s hospitals and community which was 
attributed to movement of the same major OXA-48 encoding plasmid spreading across 
the borders of Africa and the Middle East.
34
 In the current study, the two OXA-48 
producing Klebsiella pneumoniae strains were isolated from Effia-Nkwanta Regional 
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Hospital in the Western region of Ghana and AngloGold Ashanti Mines hospital in the 
Ashanti region. The two hospitals are about 200 kilometres apart, suggesting that OXA-
48 producing strains may be widespread in Ghana. As shown by the phylogenetic 
analysis, carbapenemase genes harboured by the CR isolates appear to be highly 
diverse, signalling that further studies on carbapenemase genes in Ghana could reveal 
novel variants from the genes detected in this study. Diversity of carbapenemase genes 
observed in this study probably indicates lack of clonal expansion of carbapenem 
resistance in Ghana, which is a very positive thing for the Ghanaian public health 
system. There is however the need for surveillance of carbapenem resistance in Ghana 
using both phenotypic and genotypic methods. 
 
There are a few limitations of the study. There were relatively small numbers of isolates 
included for certain Gram-negative bacteria such as Klebsiella pneumoniae, 
Enterobacter cloacae, and Shigella sonnei, which was unexpected. Furthermore, we did 
not screen for all known carbapenemase genes which could explain why for some 
isolates, carbapenemase genes were not observed even though the isolates concerned 
were carbapenem-resistant. For example, one of the three K. pneumoniae did not 
contain any carbapenemase genes screened, though it did carry ESBLs. It should also be 
noted that although ESBLs do not readily deactivate carbapenems, they could confer 
carbapenem resistance in combination with chromosomal porin mutations that prevent 
increase of β-lactam agents in the bacteria [35].  
 
We conclude that, in Ghana, the occurrence of carbapenem resistance is relatively low 
with high numbers of ESBL carriage, coupled with a small number of PCR-positive 
carbapenemase gene detections. The CR isolates are diverse and show limited 
relatedness to isolates from other geographical regions. This is the first report of the 
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occurrence of three significant carbapenemase genes; NDM-1, VIM-1 and OXA-48 in 
Ghanaian hospitals. This study thus provides an insight of the emerging resistance genes 
belonging to the Ambler Class B, two MBL-types; NDM-1 and VIM-1 and one non-
MBL-type, OXA-48 in the Class D group.  
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Figure 3. Distribution of carbapenemases and beta-lactamase in the study isolates 
Note: NDM-1= New Delhi metallo-β-lactamase-1, VIM-1= Verona integron-encoded 
metallo-β-lactamase-1, OXA-48= oxacillinase-48, IMP-1= imipenem-resistant 
Pseudomonas-1, KPC-1= Klebsiella pneumoniae carbapenemase-1, Psa= Pseudomonas 
aeruginosa, Acs= Acinetobacter species, Ec= Escherichia coli, Psp= Pseudomonas 

















































Table 1: Distribution of presumptive carbapenemase producers in phenotypic and 
genotypic assays among carbapenem-resistant isolates 
 
Bacterial isolate Phenotypic test Type of gene 
Organism CR 
total 





P. aeruginosa 51 5 - - 2 7 - - 
Acinetobacter spp      31 13 - - 9 - - - 
E. coli                     12 - - - 3 - - - 
P. putida                 7 - - - - 1 - - 
K. pneumoniae        3 3 - - - - 2 - 
En. cloacae              3 - 3 - - - - - 
C. sakazakii            1 - - - - - - - 
P. stuartii                  1 - - - 1 - - - 
S. sonnei                 1 - - - 1 - - - 
S. paucimobilis      1 - - - - - - - 
Total 111 21 3 - 16 8 2 - 



























assay Carbapenemase genes (26)  SE SP SE SP 
NDM-1 (16) 6.3
c 
78.9 0 0 16 (100) 
VIM-1 (8) 0 79.6 0 0 8 (100) 
OXA-48 (2) 100
d 
82.6 0 0 2 (100) 
IMP-1 (0) 0 0 0 0 0 (0) 
KPC-1 (0) 0 0 0 0 0 (0) 
 
a 
Total number of CR isolates (111) 
b 
None was detected by PCR assay 
c 
Only one MHT positive (n=1) was detected by PCR assay 
d
 All MHT positives (n=2) were detected by PCR assay 
 
Note: MHT= modified Hodge test, BADST= boronic acid-disc synergy test, n= number, SE= 

















 Total number of carbapenemase-positive gene(s) obtained from each hospital 
 -= no carbapenemase-positive gene found; KBTH, GA/R= Korle Bu Teaching Hospital, Greater Accra Region; ENRH, W/R= Effia Nkwanta Regional Hospital, 



























2 NDM-1  
   7 VIM-1 
9 NDM-1 3 NDM-1 1 VIM-1 - - - 1 NDM-1 - - 
ENRH, 
W/R (1) 
- - - - - 1 OXA-48 - - - - 
AGAMH, 
A/R (1) 
- - - - - 1 OXA-48 - - - - 
HRH, 
V/R (1) 
- - - - - - - - 1NDM-1 - 
25 
 
Supplementary Table 1: Primer sets for amplification of carbapenemase and extended 
spectrum β-lactamase genes 











232 Initial denaturation at 
95ºC for 3 minutes, 
followed by 40 
cycles of 
denaturation at 95ºC 
for 1 minute, 
annealing at 58ºC for 
30 seconds, and 
elongation at 72ºC 
for 1 minute 30 
seconds, followed by 
a final elongation 
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blaTEM Forward – TCAACATTTTGTCGTCG 
Reverse – 
CTGACAGTTACCAATGCTTA 
860 Initial denaturation 
15 minutes at 95
o
C 












for each primer set 
for TEM and SHV 






















Note: IMP, imipenem-resistant Pseudomonas; VIM, Verona integron-encoded metallo-β-
lactamase; OXA-48, oxacillinase-48; NDM, New Delhi metallo-β-lactamase; KPC, Klebsiella 
pneumoniae carbapenemase; TEM-1, Temoniera-1; SHV-1, sulphydry1 variable-1 
 
